Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 8/20 | 0.63 |
| ▸ | HTR2C | P28335 | 6/20 | 0.63 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10199629 | 0.77 | HTR2A (1.00) | HTR2AHTR2CMTNR1AMTNR1B | |
| SCHEMBL7734067 | 0.76 | MTNR1A (0.41) | HTR2AHTR2CMTNR1AMTNR1B | |
| SCHEMBL9079125 | 0.72 | HTR2A (0.89) | HTR2AHTR2CMTNR1AMTNR1B | |
| SCHEMBL5796602 | 0.65 | KDM4E (0.39) | HTR2AHTR2CMTNR1AMTNR1BKDM4E | |
| SCHEMBL6325423 | 0.63 | MCL1 (0.33) | HTR2AHTR2C | |
| SCHEMBL2345293 | 0.61 | HTR2A (0.70) | HTR2AHTR2CMTNR1AMTNR1BKMT2A | |
| SCHEMBL27568441 | 0.61 | HTR2A (0.30) | HTR2AHTR2C | |
| SCHEMBL2349253 | 0.60 | HTR2A (0.69) | HTR2AHTR2CMTNR1AMTNR1B | |
| SCHEMBL10199858 | 0.60 | HTR2A (1.00) | HTR2AHTR2CTRPM8 | |
| Hydrochloric Acid SCHEMBL20563150 | 0.60 | KMT2A (0.39) | HTR2AHTR2CKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960608-B2 | Intraocular pressure | ALCON, INC. (CH) | 2005-11-01 | — | — | US | disclosed |
| US-6933392-B2 | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma | ALCON, INC. (CH) | 2005-08-23 | — | — | US | disclosed |
| US-6884816-B2 | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma | ALCON, INC. (CH) | 2005-04-26 | — | — | US | disclosed |
| US-20040106597-A1 | Novel fused indazoles and indoles and their use for the treatment of glaucoma | NOVARTIS AG (CH) | 2004-06-03 | — | — | US | disclosed |
| US-20030181504-A1 | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma | MAY JESSE A (US) | 2003-09-25 | — | — | US | disclosed |
| US-20030181503-A1 | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma | NOVARTIS AG (CH) | 2003-09-25 | — | — | US | disclosed |
| US-20030083346-A1 | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma | ALCON, INC. (CH) | 2003-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181503-A1 | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma | CYP11B1, CYP11B2, SQLE | HTR2A 3176/4885HTR2C 2661/4885MTNR1A 742/4885 |
| US-20030083346-A1 | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma | CYP11B1, CYP11B2, SQLE | HTR2A 3176/4885HTR2C 2661/4885MTNR1A 742/4885 |
| US-20030181504-A1 | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma | CYP11B1, CYP11B2, SQLE | HTR2A 3176/4885HTR2C 2661/4885MTNR1A 742/4885 |
| US-20040106597-A1 | Novel fused indazoles and indoles and their use for the treatment of glaucoma | IDO1, IDO2, GLI1 | HTR2A 947/4885HTR2C 958/4885MTNR1A 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.